Incyte Co. (NASDAQ:INCY) Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group grew its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 1,456.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 195,393 shares of the biopharmaceutical company's stock after acquiring an additional 182,836 shares during the period. Schroder Investment Management Group owned 0.10% of Incyte worth $13,369,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Public Sector Pension Investment Board raised its position in shares of Incyte by 4.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 6,622 shares of the biopharmaceutical company's stock valued at $438,000 after purchasing an additional 300 shares during the period. Verition Fund Management LLC bought a new stake in Incyte during the third quarter valued at about $2,675,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Incyte in the third quarter valued at about $33,000. Investment Management Corp of Ontario boosted its stake in shares of Incyte by 4.7% in the third quarter. Investment Management Corp of Ontario now owns 26,880 shares of the biopharmaceutical company's stock worth $1,777,000 after acquiring an additional 1,200 shares during the period. Finally, Quantinno Capital Management LP grew its position in shares of Incyte by 106.5% during the third quarter. Quantinno Capital Management LP now owns 67,968 shares of the biopharmaceutical company's stock worth $4,493,000 after purchasing an additional 35,054 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have weighed in on INCY shares. Morgan Stanley dropped their price target on Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, March 24th. William Blair cut shares of Incyte from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 18th. Royal Bank of Canada decreased their price target on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating on the stock in a research note on Tuesday, February 11th. Citigroup cut their price objective on Incyte from $97.00 to $88.00 and set a "buy" rating for the company in a research report on Tuesday, February 11th. Finally, JMP Securities reiterated a "market perform" rating on shares of Incyte in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $74.88.

Insider Transactions at Incyte

In related news, EVP Sheila A. Denton sold 14,069 shares of the business's stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the transaction, the executive vice president now directly owns 25,848 shares in the company, valued at $1,914,561.36. The trade was a 35.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven H. Stein sold 12,352 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,827 shares of company stock valued at $3,322,618 in the last 90 days. Insiders own 17.60% of the company's stock.

Incyte Stock Down 5.5 %

Shares of NASDAQ:INCY traded down $3.32 on Tuesday, reaching $56.97. The company had a trading volume of 2,845,082 shares, compared to its average volume of 2,358,011. The firm has a market capitalization of $11.03 billion, a PE ratio of 211.01, a PEG ratio of 0.41 and a beta of 0.89. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. Incyte Co. has a 52-week low of $50.35 and a 52-week high of $83.95. The firm's 50 day simple moving average is $67.51 and its 200-day simple moving average is $69.81.

Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. As a group, analysts expect that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.